Prelude Therapeutics Inc company info

What does Prelude Therapeutics Inc do?
Prelude Therapeutics (NASDAQ:PRLD) is a biotechnology company dedicated to advancing innovative treatments in oncology and rare diseases. With a keen focus on drug discovery and development, Prelude is working diligently to bring novel cancer therapies from the laboratory to clinical trials, aiming to address unmet medical needs. Their pipeline includes a range of small-molecule therapeutics designed to target key signaling pathways in cancer cells, showcasing their commitment to transforming the landscape of cancer treatment. Central to the company's objectives is the pursuit of scientific breakthroughs that can lead to life-changing treatments for patients battling cancer and other serious diseases.
Prelude Therapeutics Inc company media
Company Snapshot

Is Prelude Therapeutics Inc a public or private company?

key
Ownership
Public

How many people does Prelude Therapeutics Inc employ?

people
Employees
128

What sector is Prelude Therapeutics Inc in?

pie chart
Sector
Health Care

Where is the head office for Prelude Therapeutics Inc?

location pin
Head Office
Wilmington, United States

What year was Prelude Therapeutics Inc founded?

founded flag
Year Founded
2016
What does Prelude Therapeutics Inc specialise in?
/Cancer Therapeutics /Drug Discovery /Preclinical Studies /Cancer Research /Biomarker Discovery /Clinical Trials

What are the products and/or services of Prelude Therapeutics Inc?

Overview of Prelude Therapeutics Inc offerings
PRT543, a small molecule inhibitor targeting PRMT5, designed for treating a variety of cancers including solid tumors and hematological malignancies.
PRT811, a PRMT5 inhibitor with potential broad application in solid tumors, particularly glioblastoma.
PRT2527, a CDK9 inhibitor aiming at treating MYC-driven cancers, including hematologic malignancies and solid tumors.
PRT1419, an MCL1 inhibitor intended for patients with hematologic malignancies, addressing a key survival protein in cancer cells.
PRT3645, a potent inhibitor focusing on PI3K delta, developed for treating hematologic malignancies.

Who is in the executive team of Prelude Therapeutics Inc?

Prelude Therapeutics Inc leadership team
  • Dr. Krishna  Vaddi D.V.M., Ph.D.
    Dr. Krishna Vaddi D.V.M., Ph.D.
    Founder, CEO & Director
  • Dr. Edna  Huang M.D.
    Dr. Edna Huang M.D.
    President & Chief Medical Officer
  • Dr. Peggy A. Scherle Ph.D.
    Dr. Peggy A. Scherle Ph.D.
    Chief Scientific Officer
  • Mr. Laurent  Chardonnet M.B.A.
    Mr. Laurent Chardonnet M.B.A.
    Chief Financial Officer
  • Ms. Aimee  Crombie Ph.D.
    Ms. Aimee Crombie Ph.D.
    Senior VP and Head of Strategic Planning & Operations
  • Dr. Madhu  Pudipeddi Ph.D.
    Dr. Madhu Pudipeddi Ph.D.
    Senior Vice President of Technical Operations
  • Lindsey  Trickett
    Lindsey Trickett
    Vice President of Investor Relations
  • Mr. Bryant David Lim J.D.
    Mr. Bryant David Lim J.D.
    Chief Legal Officer & Corporate Secretary